Objective To investigate the relationship between the gene polymorphisms of thromboxane A2 receptor (TXA2R) and cerebral infarction. Methods A genetic association study of one single nucleotide polymorphism (rs768963) in the human TXA2R gene was performed in 334 patients with cerebral infarction and 135 healthy controls by polymerase chain reaction-amplification and restriction fragment length polymorphism(PCR-RFLP) method. Results The levels of blood pressure,blood-fat and serum glucose were independent risk factors for cerebral infarction. No significant differences in the overall distribution of genotypes (T/T, T/C and C/C) were noted (P＞0.05); however,significant differences in T or C gene frequency of rs768963 of TXA 2R gene between patients with cerebral infarction and noninfarction controls were found (P＜0.05). Logistic regression analysis showed that no association between the mutant of rs768963 of TXA 2R gene and such factors as gender, age and levels of blood fat, blood pressure and serum glucose was noted. Conclusion The rs768963 of TXA 2R gene in human thromboxane A2 receptor may be a risk factor for cerebral infarction and patients carried C allele are much likely to have cerebral infarction.

Aim To explore the impacts of high mobility group box 1 (HMGB1) on the phenotypes, endocy-tosis and extracellular signal-regulated kinase (ERK)/ Jun N-terminal protein kinase (JNK)/P38 mitogen-ac-tivated protein kinase (MAPK) signaling pathway in indoxyl sulfate (IS) -induced dendritic cells (DCs). Methods After treatment with 30, 300 and 600 (xmol · L

OBJECTIVE: To observe the rehabilitation effect of non-invasive positive pressure ventilation( NPPV) in treating pneumoconiosis patients with pulmonary dyspnea. METHODS: A retrospective analysis was used to analyze the treatment compliance,treatment time,treatment effect and adverse reactions of 295 pneumoconiosis patients who had undergone inpatient NPPV treatment. RESULTS: The median of NPPV treatment time of 295 pneumoconiosis patients was 14( 1-281)days. The treatment compliance rate was 79. 66 %( 235 /295). The dyspnea improvement rate was 73. 22 %( 216 /295).The Chi-square test results showed that the dyspnea improvement rate increased with the prolonged treatment time( P <0. 01). Among these,the dyspnea improvement rates of groups with treatment time of 10 days,20 days and ≥ 30 days were higher than group with treatment time < 10 days,the dyspnea improvement rate of the group with treatment time ≥30days was higher than 10 days group( P < 0. 01). The incidence of adverse reactions was 7. 12 %. CONCLUSION: NPPV treatment could improve dyspnea symptoms of pneumoconiosis patients with less adverse reaction.